News & Updates
Filter by Specialty:
Obesity med cessation more likely after RYGB than sleeve gastrectomy
Patients who are on obesity-related medications before undergoing bariatric surgery may be more likely to discontinue their medications and less likely to restart them after undergoing Roux-en-Y gastric bypass (RYGB) than laparoscopic sleeve gastrectomy (LSG), a recent study has shown.
Obesity med cessation more likely after RYGB than sleeve gastrectomy
15 Apr 2022
Maintenance selinexor promising for PFS in advanced/recurrent endometrial cancer
Maintenance treatment with selinexor improved progression-free survival (PFS) in patients with advanced or recurrent endometrial cancer who had previously received first-line chemotherapy, particularly those with endometrioid histology and wild-type p53, according to a study presented at SGO 2022.
Maintenance selinexor promising for PFS in advanced/recurrent endometrial cancer
14 Apr 2022
Second-line ustekinumab for Crohn’s disease holds up in real world, as good as vedolizumab
Ustekinumab is well tolerated and proves to be effective in the second-line treatment of patients with Crohn’s disease, according to real-world data from the Cross Pennine II study. Furthermore, while clinical remission appears to occur sooner with ustekinumab than with vedolizumab, the two drugs perform comparably at maintaining remission over 12 months.